Raphael Pharmaceutical Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RAPH research report →
Price Chart
About the company
Raphael Pharmaceutical Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering and clinically developing novel therapeutic solutions. These treatments primarily leverage cannabinoids and are designed to enhance patients' quality of life.
- CEO
- Shlomo Pilo
- IPO
- 2023
- HQ
- Jaffa, TA, IL
Get TickerSpark's AI analysis on RAPH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $28.25M
- P/E
- -28.46
- PEG
- -0.60
- P/S
- 0.00
- P/B
- -14.99
- EV/EBITDA
- -30.55
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 62.78%
- ROIC
- 50.33%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,245,000
- Net Income
- $-1,279,000+15.8%
- EPS
- $-0.07+19.6%
- OCF Growth
- +60.5%
- FCF Growth
- +60.5%
- 52W High
- $1.40
- 52W Low
- $0.04
- 50D MA
- $1.40
- 200D MA
- $1.40
- Beta
- 1.90
- RSI (14)
- 52
- Avg Volume
- 3
No earnings-call transcripts are available for RAPH yet.
- Free Float
- 57.1%
- Shares Outstanding
- 20.18M
- Float Shares
- 11.52M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 20, 25 | Louria Hayon Igal | other | 350,000 |
| Nov 20, 25 | Louria Hayon Igal | other | 350,000 |
| Aug 1, 25 | Laor Zvi Laufer | other | 0 |
| Mar 10, 25 | Eliya Yehuda | other | 200,000 |
| May 12, 22 | Eliya Yehuda | other | 202,000 |
| Mar 2, 25 | Pilo Shlomo | other | 200,000 |
| Mar 2, 25 | Pilo Shlomo | other | 100,000 |
| Mar 5, 25 | Dhadha Ajay Kumar | other | 350,000 |
| Mar 5, 25 | Dhadha Ajay Kumar | other | 250,000 |
| Jan 8, 25 | Dhadha Ajay Kumar | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RAPH coverage
Recent articles, reports, and earnings notes.
No research on RAPH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RAPH report →Raphael Pharmaceutical Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid Arthritis (RA)
globenewswire.com · Nov 17
Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company's Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis
globenewswire.com · Jan 7
Raphael Pharmaceutical Issues Letter to Shareholders
globenewswire.com · Jul 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.